Results 211 to 220 of about 586,922 (305)

Fibroblast Plasticity in Inflammation of the Barrier

open access: yesBarrier Immunity, EarlyView.
Under inflammatory condition, fibroblasts in barrier tissues integrate inflammatory, senescent, and mechanical inputs. These pathways activate central signaling networks to drive fibroblast phenotypic transition, enabling cytokine production, immune cell recruitment, and extracellular matrix remodeling.
Chen Zhang, Hao Wu, Wei Li
wiley   +1 more source

Pss knockdown in the midgut causes growth retardation in Drosophila similar to that in human LMHD

open access: yesDevelopmental Dynamics, EarlyView.
Abstract Background Phosphatidylserine synthase (PSS), localized in the mitochondrial membrane, synthesizes phosphatidylserine. In humans, mutations in Pss lead to Lenz–Majewski hyperostotic dwarfism, a disorder affecting growth and development. The effects of Pss mutations on the growth of Drosophila melanogaster are not fully known. Hence, this study
Kwan‐Young Kim   +4 more
wiley   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li   +12 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

SV2A expression in blood cells as a possible biomarker candidate for levetiracetam treatment response

open access: yesEpilepsia, EarlyView.
Abstract Objective This study was undertaken to evaluate whether synaptic vesicle protein 2A (SV2A) expression on peripheral immune cells predicts treatment response to levetiracetam in epilepsy. Methods High‐dimensional flow cytometry was used to prospectively assess SV2A expression on immune cells from levetiracetam responders, nonresponders, and ...
Johannes Lang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy